Retatrutide: Triple-Receptor Weight Loss, Liver Fat, and Dose Logic

Retatrutide Dosage by Body Type

The dose that produced 24% weight loss in the Phase 2 trial was measured in one kind of body: average BMI 37, around 110 kg, sedentary, non-diabetic.⁶ A 75 kg lean person taking the same milligrams is not taking the same drug, so the chart below is built by body type rather than presented as one ladder with footnotes.

Two things shift the moment the body changes. A lighter body has less blood to dilute the dose, so a 75 kg person sees roughly 20 to 40% more drug per kilogram than the trial cohort at the same dose.⁷ The larger difference is the heart. A metabolically healthy cardiovascular system reads the same glucagon signal far harder, and a lean user has no large weight loss to bring the rate back down.⁸

Trial-cohort obese — BMI 30 to 40, non-diabetic. The published anchor. A practical start is 0.5 mg, building through 1, 1.5, 2, 2.5, 3, 3.5, then 4 or 5 mg, holding four weeks per step. The 1 mg arm is the lowest dose with direct human weight-loss data: 8.7% at 48 weeks.⁶ The 6 to 9 mg band is high-efficacy territory for higher adiposity, fatty liver, or a stalled response.

Metabolically healthy lean — BMI 22 to 28. Start at 0.3 mg. The effective bands compress, so meaningful results often appear at 2 to 4 mg rather than 6 to 8 mg, and the heart-rate cost is the dominant concern rather than nausea. Track resting heart rate weekly through any dose increase. This phenotype sits outside the published trial population, so its dosing is reasoned from the receptor pharmacology and Phase 1 single-dose data, not measured in a chronic lean trial.

Type 2 diabetic obese — BMI 30 to 40. Blood-sugar improvement is the loud signal here, with HbA1c falling 1.39% at 4 mg over 36 weeks.⁹ Years of high glucose blunt part of the GIP response, but retatrutide's high GIP-receptor engagement pushes through some of that. The heart-rate signal is quieter than in lean users, because long-standing metabolic disease blunts the cardiovascular response, while the kidney and liver benefits of the glucagon arm are central for this group.

Across every body type the ladder reads in four lanes:

• Microdose, 0.3 to 1 mg. GIP-forward. The liver and visceral-fat signal begins and appetite eases without forcing.
• Standard, 1 to 5 mg. The main weight-loss range, where appetite suppression establishes and the glucagon arm builds.
• High-efficacy, 6 to 9 mg. Added weight loss comes from appetite and glucagon signal; the GIP arm is saturated. 9 mg is the routine high-dose target in Phase 3.
• Escalation, 10 to 12 mg. The 8 to 12 mg step buys little extra average weight loss for a real increase in side effects. It matters mainly for the deepest responders and for liver and visceral-fat goals.

The single rule that prevents most trouble is to hold each dose for at least four weeks before increasing. Retatrutide's six-day half-life means a new dose does not reach steady plasma levels for almost three weeks, so a heart-rate or nausea response to one step can appear after a person has already moved to the next.¹⁰

Speed matters more than the destination. The same final dose, reached fast or slow, produces different tolerability. The brainstem circuit that buffers nausea has to fire alongside a low GLP-1 signal long enough to wire in; fast escalation hits the nausea pathway before that brake is built.¹ In the Phase 2 trial, the arm that jumped in 4 mg steps carried sustained gastrointestinal symptoms across 48 weeks, while every slower arm faded to single-digit rates by month nine.⁶

Two practical consequences follow. Do not skip bridge rungs on the way up; the calculator inserts 5 and 6 mg steps before 8 or 9 mg for that reason. And consider splitting the weekly dose at 4 mg and above. Gastrointestinal and heart-rate effects track the peak concentration after each injection, not the weekly total, so dosing every three days delivers the same cumulative exposure at a lower peak and improves tolerability without changing efficacy.

The headline figures are the Phase 2 obesity result of 24.2% mean weight loss at 12 mg over 48 weeks, and the Phase 3 TRIUMPH-4 result of 28.7% at 12 mg over 68 weeks in obesity with osteoarthritis.⁶ ¹¹ Across the dose range, the response follows a curve rather than a straight line: half of the maximum effect arrives by about 4 mg, and 8 mg already captures roughly 94% of what 12 mg delivers.⁴ ¹²

The trajectory is gradual. Weight loss at week 24 is roughly three-quarters of the eventual result, appetite reaches most of its long-run effect by week 24, and liver-fat reduction is still moving at week 48. Two person-level factors move the expected number more than most people assume. Women lose meaningfully more than men at the same dose, with the female advantage in obesity around 4 kg, the largest of any compound studied.¹³ And the effect declines with age, by roughly 3% for each year above 50, independent of body type.¹²

These figures come from the trials. A lean recomposition user starting at a normal body weight should expect a smaller absolute loss in kilograms, though it can be proportionally meaningful, and no chronic trial has measured that population directly.

Retatrutide and Liver Fat

The glucagon arm is what makes retatrutide a liver drug, not only a weight drug. Glucagon signals the liver to oxidize its own stored fat, an effect semaglutide and tirzepatide cannot produce because they do not engage the glucagon receptor.³

In the MASLD substudy, which enrolled only people with at least 10% liver fat, liver fat fell 51% at 1 mg and 86% at 12 mg over 48 weeks, and steatosis resolved in 93% of participants at the top dose.¹⁴ The effect is substrate-gated. A person with a fatty liver has fat to mobilize, so the reduction is large and measurable. A lean person without liver fat shows the same biochemical signal of fat-burning, a rise in ketones, but has no stored liver fat to deplete, so a liver-fat scan would show little to reduce. The same glucagon engagement, read through a different liver, gives a different result.

The glucagon arm also lowers triglycerides and LDL cholesterol by releasing the brake on an enzyme that clears fat from the blood, with triglycerides falling around 60% and LDL around 25% at the top dose.¹⁵

Body Composition and Titration Speed

Not all weight lost is fat, and titration speed changes the ratio. In the trial, the arm that titrated slowly lost less total weight, but what came off was overwhelmingly belly fat. The arm that titrated fast lost more total weight, and a larger share of it was water, lean mass, and subcutaneous fat rather than visceral fat.⁶

The mechanism is intake. Slow titration keeps a person near normal eating in the early weeks, so a modest glucagon signal can preferentially mobilize visceral fat, where the glucagon receptor is densest. Fast titration forces a steep calorie deficit through nausea, and a deficit that severe pulls fuel from everywhere, including muscle.

Across the class, roughly a quarter of weight lost is fat-free mass, and about half of that is skeletal muscle.¹⁶ For a heavier person this is a small fraction of a large loss. For a lean user with less reserve, it is a higher-resolution concern, which is one more reason the lean phenotype favors a slower, lower-dose approach with resistance training and adequate protein.

Side effects on retatrutide come from two receptor sources. The GLP-1 arm drives the familiar gastrointestinal effects: nausea, vomiting, diarrhea, and slowed digestion. These scale with dose, peak during titration, and partially settle over time; slow titration and smaller, protein-anchored meals are the main levers. The same GLP-1 arm drives a less familiar effect at the upper doses: a burning or tingling skin sensitivity (dysesthesia). It is not the glucagon arm, and it is not unique to retatrutide — high-dose semaglutide, which has no glucagon action at all, carries it too, so it tracks the GLP-1 signal. The mechanism is not settled; the leading explanation is that the drug turns up one pain-signaling channel on skin nerves rather than switching those nerves on, which is why the same class improves nerve pain in damaged diabetic nerves while irritating healthy ones at high dose. It is usually mild, eases on a dose drop, and clears by 1 to 2 mg.¹⁷ The glucagon arm adds a different effect the GLP-1 class does not: it can slow the conversion of thyroid hormone into its active form, which may present as unexplained fatigue or cold intolerance. Because that lowers free T3 while leaving TSH normal, a standard thyroid panel can miss it; free T3 is the marker to check.

A baseline panel before starting makes every later decision interpretable: resting heart rate recorded over a week, fasting glucose and HbA1c, a lipid panel, a thyroid panel including free T3, and liver enzymes.

One honest limitation. The trial adverse-event tables are pre-specified inventories, so an effect that was not listed for capture does not appear, whether or not participants experienced it. Several commonly searched symptoms, including hair loss, sit outside the trial-captured set, so the published data is genuinely silent on them rather than reassuring. Where that is the case, this guide says so rather than filling the gap.

A fuller treatment of each side effect lives in the dedicated retatrutide side-effects guide.

The heart-rate rise is real, and it is mostly the glucagon arm. The GLP-1 class on its own raises resting heart rate by only 2 to 4 bpm even at maximum dose; retatrutide's larger signal sits on top of that flat floor and tracks the glucagon engagement.⁸ In the obese trial cohort it peaked around 6 to 9 bpm at 12 mg near week 24, then eased toward 5 bpm by week 48 as substantial weight loss brought the system back into balance.⁶

The phenotype split matters here more than anywhere. A lean, fit person runs a more responsive cardiovascular system, so the same glucagon engagement can land several times harder, and without a large weight loss there is no compensating decline. The cost per beat is also real: each sustained extra beat per minute adds a modest daily energy demand from heart muscle. For users at 6 mg and above, a smartwatch ECG check at each step is worth doing, and pre-existing atrial fibrillation or known structural heart disease is a clear reason not to use retatrutide.

Microdosing Retatrutide

Microdosing retatrutide has the strongest evidence base of any microdose claim in the GLP-1 class, because the 1 mg arm was a directly measured trial arm rather than an extrapolation. At 1 mg the GIP receptor is already roughly half-engaged and the liver is already burning fat, while the appetite and heart-rate signals stay light.⁴ ⁶

The point is that a microdose is not a weak version of a full dose. It is a different signal mix, weighted toward the GIP arm, with much less of the glucagon-driven heart-rate cost. A common lighter-user ladder runs 0.1, 0.3, then 0.5 mg, with four weeks per step. Doses below 1 mg are supported by Phase 1 acute data and the receptor model rather than by chronic outcome trials, so the lower the dose, the more the logic rests on mechanism rather than measured outcomes.

Stopping Retatrutide

Stopping retatrutide does not cause a physical withdrawal syndrome, but it does set up weight regain, and the pressure is expected to be stronger than with semaglutide or tirzepatide. Four forces converge. Appetite returns as the drug clears over about 30 days. Any lean mass lost during the deficit lowers daily energy use. Hunger-hormone signals stay elevated for up to a year after major weight loss.¹⁸ And, unique to retatrutide, the glucagon-driven defense of resting metabolism fades within weeks of the last dose, removing a support the other drugs never provided.

There is no published retatrutide taper, so the framework below is reasoned from the dose-response data and from semaglutide and tirzepatide withdrawal trials. A taper is behavioral, not a detox: it buys 8 to 12 weeks of lower-but-present appetite suppression in which to rebuild lean mass and lock in eating and training habits. A practical shape is a maintenance hold at 2 to 4 mg, then a slow step-down, with resistance training and at least 1.6 g/kg of protein per day carrying the muscle-preservation load throughout.

Retatrutide vs Tirzepatide

The mechanistic difference is one receptor. Retatrutide adds the glucagon arm that tirzepatide does not engage at all, and it binds the GIP receptor far more tightly, so meaningful GIP engagement arrives at a fraction of the dose. The glucagon arm is what gives retatrutide its liver-fat reduction, its defense of resting metabolism, and its larger heart-rate cost.

The two also differ at the receptor they share, in a way raw engagement hides. Retatrutide engages more of the GLP-1 receptor per dose, but tirzepatide gets more lasting signal out of each receptor it engages, because it barely triggers the receptor's own wind-down switch. Comparing the two on GLP-1 engagement alone therefore overstates retatrutide's edge there. The real separation between them is the glucagon arm, not the GLP-1 one.

On weight loss the head-to-head trial has not read out yet. Cross-trial, tirzepatide produced about 21% at 15 mg over 72 weeks, while retatrutide produced 24% at 12 mg over 48 weeks in Phase 2 and 29% in Phase 3 TRIUMPH-4; the numbers favor retatrutide, but differences in cohort and trial length make a precise gap unreliable until the direct comparison reports.⁶ ¹¹ For switching, the key point is not to carry a maximum tirzepatide dose straight across. Tirzepatide builds tolerance to two of retatrutide's three receptors but none to the glucagon arm, so starting retatrutide at 1 to 2 mg gives that new system time to adjust.

A full comparison lives in the dedicated retatrutide versus tirzepatide guide.

Frequently Asked Questions

References

¹ GIP receptor — fat-cell energy handling via SERCA-mediated futile calcium cycling, and brainstem GABAergic antiemetic buffering: Yu et al. 2025 Cell Metabolism; Hayes, Borner & De Jonghe 2021 Diabetes.

² GLP-1 receptor — appetite suppression at hypothalamic and brainstem sites, vagal-mediated gastric slowing, area-postrema nausea pathway: Secher et al. 2014 J Clin Invest; Holst 2007 Physiol Rev.

³ Glucagon receptor — hepatic fatty-acid oxidation, resting-energy-expenditure preservation, and the dose-scaling cardiac contribution; tonic chronic engagement via hepatocyte PDE4B/4D downregulation: Long et al. 2025; Goodman et al. 2025 Br J Clin Pharmacol.

⁴ Receptor potency and engagement by dose — GIP-receptor binding roughly an order of magnitude tighter than tirzepatide; 8 mg captures ~94% of the 12 mg mean effect: Coskun et al. 2022 Cell Metabolism; Jastreboff et al. 2023 NEJM.

⁵ GLP-1-receptor occupancy approximately half-engaged at 12 mg, still on the climbing portion of its dose-response curve: receptor model from Coskun 2022 EC50 values and steady-state exposure.

⁶ Phase 2 obesity trial — dose-response weight loss, MASLD substudy, titration-speed adverse-event pattern, body-composition partition: Jastreboff et al. 2023 NEJM 10.1056/NEJMoa2301972.

⁷ Body-weight exposure shift — lighter body weight raises exposure per dose; derived from tirzepatide population pharmacokinetics and retatrutide allometric validation: Schneck & Urva 2024 CPT Pharmacometrics Syst Pharmacol.

⁸ Cardiac chronotropy — additive composite, GLP-1 floor of +2 to 4 bpm with glucagon carrying the dose-scaling majority; amplified in lean, responsive cardiovascular states: Goodman et al. 2025 Br J Clin Pharmacol; Lubberding et al. 2024 Cardiovasc Res; Petersen et al. 2020 JAHA.

⁹ Phase 2 type 2 diabetes trial — HbA1c reduction by dose: Rosenstock et al. 2023 Lancet.

¹⁰ Six-day half-life and steady-state kinetics; titration adaptation timing: Coskun et al. 2022 Cell Metabolism.

¹¹ Phase 3 TRIUMPH-4 — 28.7% weight loss at 12 mg over 68 weeks in obesity with osteoarthritis: Eli Lilly press release, December 2025 investor.lilly.com.

¹² Class dose-response and age covariate — model-based meta-analysis, retatrutide Emax and ED50, ~3% effect decline per year above ~50: Guo et al. 2025.

¹³ Sex-stratified meta-analysis — female weight-loss advantage, ~4.2 kg at the obesity indication: Yang et al. 2025 J Diabetes.

¹⁴ MASLD substudy — liver-fat reduction by dose and steatosis-resolution rate: Sanyal et al. 2024 Nature Medicine s41591-024-03018-2.

¹⁵ Lipid mechanism — glucagon-driven ANGPTL3/8 suppression, triglyceride and LDL reduction: Wen et al. 2025 Diabetes Obes Metab.

¹⁶ Lean-mass partition — roughly 25% of weight loss as fat-free mass, about half skeletal muscle, across the GLP-1 class: Nuijten et al. 2022 Obes Rev; Conte et al. 2024 JAMA.

¹⁷ Dysesthesia as a GLP-1-class effect at upper doses — not the glucagon arm (high-dose semaglutide, with no glucagon action, carries it); enhanced ATP/P2X pain-signaling on skin sensory neurons with TRPV1 excluded: Anand et al. 2018 PLoS ONE. Denominator-controlled cohort (incident allodynia HR 2.15 vs an active weight-loss comparator): Frey et al. 2026 medRxiv. Retatrutide trial rates: Jastreboff et al. 2023 NEJM supplementary tables. Thyroid T3 suppression presenting with normal TSH: mechanism review.

¹⁸ Persistence of hunger-hormone adaptations for up to a year after major weight loss: Sumithran et al. 2011 NEJM 10.1056/NEJMoa1105816.